Skip to content

Immersive Mixed Reality Simulation to Evoke Empathy

Immersive Mixed Reality Simulation to Evoke Empathy

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06351397
Acronym
Empathy
Enrollment
81
Registered
2024-04-08
Start date
2025-01-24
Completion date
2025-10-08
Last updated
2026-01-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Educational Problems

Keywords

Virtual Reality

Brief summary

This is a quantifiable study evaluating the ability of a mixed reality (MR), immersive simulation experience to evoke empathy in anesthesiology trainees. Quantitative methodologies will be employed using standardized questionnaires including the The Jefferson Scale of Physician Empathy for Health Professions Students, (HP-version). Trainees will assess their preliminary, baseline empathy using the Jefferson Scale and after the simulation and debrief, will reassess empathy scores, once again using the Jefferson Scale. A satisfaction survey to assess simulated patient embodiment as a valuable exercise and contributor to empathy education curriculum.

Interventions

BEHAVIORALMixed Reality (MR)

Mixed Reality simulation of medical crisis scenarios. MR headset - a device that the participants will wear over their head and eyes and will add holographic elements to a live view of workplace training scenario

BEHAVIORALControl

Tradition simulation of medical crisis scenarios.

Sponsors

Stanford University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
Yes

Inclusion criteria

* Trainees or personnel working and/or volunteering at Lucile Packard Children's Hospital Stanford / Stanford Health Care facilities * 18 years and older

Exclusion criteria

* a history of severe motion sickness * currently have nausea * have a history of seizures * are uncomfortable wearing a \~7 pound weighted vest.

Design outcomes

Primary

MeasureTime frameDescription
Changes in self-reported empathy from before and after the simulationbaseline, immediately after the interventionMeasured with Jefferson Scale of Physician Empathy for physicians and other practicing health professionals (HP-Version). The survey contains 20 item with 7-point scale, 1 indicates strongly disagree and 7 indicates strongly agree (a higher number on the scale indicates more agreement).

Secondary

MeasureTime frameDescription
Satisfaction of Design Features of the Simulationimmediately after the interventionMeasured by Simulation Design Scale. The simulation design scale consists of 20 items in total. In the first stage, in order to evaluate whether the items used in the simulation method were given in the best way for the participant, they were expressed as strongly disagree, disagree, undecided, agree, strongly agree. The survey contains 20 item with 5-point scale, 1 indicates strongly disagree and 5 indicates strongly agree (a higher number on the scale indicates more agreement). In the second stage, there are statements that will determine the level of importance of the scale items for the participant, not important, partially important, undecided, important, very important. The survey contains 20 item with 5-point scale, 1 indicates not important and 5 indicates very important (a higher number on the scale indicates more important). In the evaluation phase, the scale score is calculated by dividing the total and the total of the sub-dimensions by the number of items.
Evaluation of the CHARM system's usabilityimmediately after simulationMeasured by System Usability Scale (SUS). The scale has 10 items. Scores ranges from 1-5 (1 = strongly disagree and 5 = strongly agree)
Evaluation of the CHARM system's ergonomicsimmediately after simulationMeasured by the ISO Ergonomic scale. The scale has 6 items. Scores ranges from 1-5 (1 = strongly disagree and 5 = strongly agree)

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026